+26.2%
KLAC vs MRNA
+945.0%
-918.8%
-51.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | +13.1% | -17.2% | -4.2% |
| 7D | -5.7% | +20.6% | -26.3% | -5.8% |
| 30D | -27.6% | +27.1% | -54.7% | -27.7% |
| 3M | -23.3% | +353.4% | -376.7% | -25.1% |
| 6M | -12.4% | +446.3% | -458.6% | -20.7% |
| YTD | +23.7% | +776.2% | -752.4% | +1.7% |
| 1Y | +26.2% | +987.9% | -961.7% | -1.2% |
| All | +26.2% | +945.0% | -918.8% | -1.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling